The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers

The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers

July 13, 2022 • By Joseph Cantrell, JD, & Kenneth G. Saag, MD, MSc

  • Tweet
  • Email
Print-Friendly Version / Save PDF
The U.S. Supreme Court

The U.S. Supreme Court

On June 24, the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization. The consequences of overturning the 50-year-old precedent established in Roe v. Wade have been profound and swift. At least 24 states have, or will soon have, bans on abortion that could expose rheumatology professionals, pharmacists and, in some cases, patients to harsh criminal and civil penalties. With abortifacient drugs, such as methotrexate, facing more scrutiny, access issues have emerged for rheumatology professionals who depend on these drugs to treat patients with rheumatic disease.

You Might Also Like
  • The ACR Responds to Reports of Treatment Denials in Wake of Dobbs v. Jackson Women’s Health Organization
  • Magnify Rheumatology’s Legislative Impact this Month
  • ACR Commends CMS Decision to Withdraw Most Favored Nation Payment Model for Part B Drugs

Protecting Rheumatology Patients & Providers

Even as the effects of the decision unfold, it is clear that the ACR has an important role to play in the national discussion. We must work to ensure that patients with rheumatic disease have access to the medications and treatments they need and that rheumatology providers are able to care for their patients as they and their patients deem necessary.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As many of you know, the ACR has a full federal and state advocacy team on staff. We are already working on advocacy strategies to protect the interests of the rheumatology community. We also must work to ensure that the privacy expected in the provider/patient relationship remains intact. To that end, the ACR has created a new Access to Reproductive Health Care Task Force, which I’m leading.

The taskforce consists of rheumatology professionals from around the U.S. It will serve as a rapid response unit to address and provide information on emerging issues following the Dobbs decision. The taskforce has been charged with providing resources and guidance documents and holding a town hall to address many of the questions that members are asking right now. The work of the task force will serve as a foundation for the ACR to develop additional plans of action through relevant committees, including the Government Affairs Committee, the Committee on Rheumatologic Care and others.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As one of the first steps, the ACR will be reaching out to state boards of pharmacy, as well as governors, legislators and other policy makers, to ensure that medications patients use chronically to manage their diseases, even those that may be teratogenic, remain accessible to rheumatology patients and to ensure that safeguards are put in place to protect members of the rheumatology care team and patients from potential penalties when using these drugs to manage rheumatic diseases. Once we have more clarity on these issues, we will work to identify and develop long-term strategic approaches that ensure the provider/patient relationship remains at the center of rheumatology care.

Pages: 1 2 3 | Single Page

Filed Under: American College of Rheumatology, Conditions, Legislation & Advocacy Tagged With: Access to care, Access to Reproductive Health Care Task Force, ACR advocacy, Legal, Methotrexate, reproductive health

You Might Also Like:
  • The ACR Responds to Reports of Treatment Denials in Wake of Dobbs v. Jackson Women’s Health Organization
  • Magnify Rheumatology’s Legislative Impact this Month
  • ACR Commends CMS Decision to Withdraw Most Favored Nation Payment Model for Part B Drugs
  • Rheumatology Patients Are Essential to the ACR’s Grassroots Advocacy

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)